Question 1

SECTION A - QUESTION 2

GenoCure is a biotechnology company developing advanced gene therapies. The company is preparing its financial statements for the year ended 31 October 20X5. GenoCure is currently seeking a lucrative Initial Public Offering (IPO) in early 20X6.

You are the newly appointed Chief Financial Officer (CFO), a qualified accountant. The Chief Executive Officer (CEO), who is also the majority shareholder, has presented you with two issues:

Issue 1: Research and Development (R&D)
During the year, GenoCure spent $12 million on a new gene therapy project, 'Helix-X'. $4 million was spent on early-stage laboratory research. The remaining $8 million was spent on Phase 1 clinical trials. While the Phase 1 trials showed promising safety profiles, efficacy has not yet been proven, and regulatory approval is at least three years away. The CEO has instructed you to capitalize the entire $12 million as an intangible asset, stating, "Our investors need to see a strong balance sheet for the IPO. If we expense this, our profit margins will look terrible, and the IPO valuation will collapse."

Issue 2: Related Party Transaction
GenoCure outsourced its data analysis for the clinical trials to 'DataGen', a company wholly owned by the CEO's brother. GenoCure paid DataGen $3 million for these services. Independent market analysis indicates that the arm's length commercial rate for identical services is $1.5 million. The CEO has told you not to disclose this transaction in the financial statements, arguing, "It's a standard service contract, and disclosing it will just invite unnecessary scrutiny from potential IPO investors."

Required:
(a) Discuss the correct accounting treatment for the R&D expenditure under IAS 38 Intangible Assets, and the transaction with DataGen under IAS 24 Related Party Disclosures. (10 marks)

(b) Discuss the ethical and professional issues you face as the CFO of GenoCure, and recommend appropriate actions you should take to resolve them. (10 marks)

Accepted Answer

1. Apply IAS 38 strictly: separate research (always expense) from development (capitalize only if PIRATE criteria met). Note that Phase 1 biotech trials rarely meet technical feasibility. 
2. Apply IAS 24: identify the related party link (close family of KMP) and mandate disclosure, especially noting the non-arm's length pricing.
3. Use the ACCA Code of Ethics framework: identify fundamental principles breached (Integrity, Objectivity, Professional Competence) and threats (Intimidation, Self-interest). Provide a step-by-step escalation plan.

Question 2

What mistakes do candidates make on this ACCA question?

Accepted Answer

Candidates often state that development costs *must* be capitalized without assessing if the specific criteria (technical feasibility, regulatory approval) are met. In ethics, candidates frequently jump straight to 'resign' without outlining the necessary escalation steps (discuss with CEO, then Audit Committee, then seek legal advice).

How to approach this question

Full Answer

Common mistakes

Practice the full ACCA SBR — Strategic Business Reporting Practice Exam 6

More questions from this exam